DK3556775T3 - Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter - Google Patents
Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter Download PDFInfo
- Publication number
- DK3556775T3 DK3556775T3 DK19161885.9T DK19161885T DK3556775T3 DK 3556775 T3 DK3556775 T3 DK 3556775T3 DK 19161885 T DK19161885 T DK 19161885T DK 3556775 T3 DK3556775 T3 DK 3556775T3
- Authority
- DK
- Denmark
- Prior art keywords
- malignities
- hematological
- lag
- antibodies
- treatment
- Prior art date
Links
- 230000002489 hematologic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461932589P | 2014-01-28 | 2014-01-28 | |
| EP15705137.6A EP3099716A1 (en) | 2014-01-28 | 2015-01-26 | Anti-lag-3 antibodies to treat hematological malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3556775T3 true DK3556775T3 (da) | 2022-01-03 |
Family
ID=52478072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19161885.9T DK3556775T3 (da) | 2014-01-28 | 2015-01-26 | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20160326248A1 (da) |
| EP (3) | EP3988572A1 (da) |
| JP (4) | JP2017505773A (da) |
| KR (2) | KR20220147714A (da) |
| CN (1) | CN105992595A (da) |
| BR (1) | BR112016017174A2 (da) |
| CA (1) | CA2937503A1 (da) |
| CY (1) | CY1124977T1 (da) |
| DK (1) | DK3556775T3 (da) |
| EA (1) | EA201691361A1 (da) |
| ES (1) | ES2902369T3 (da) |
| HR (1) | HRP20212033T1 (da) |
| HU (1) | HUE057817T2 (da) |
| LT (1) | LT3556775T (da) |
| MX (2) | MX2016009010A (da) |
| PL (1) | PL3556775T3 (da) |
| PT (1) | PT3556775T (da) |
| RS (1) | RS62788B1 (da) |
| SI (1) | SI3556775T1 (da) |
| SM (1) | SMT202200002T1 (da) |
| WO (1) | WO2015116539A1 (da) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| RS58705B1 (sr) | 2013-09-20 | 2019-06-28 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| AU2015229103C9 (en) | 2014-03-14 | 2020-11-26 | Immutep S.A.S | Antibody molecules to LAG-3 and uses thereof |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| DK3298021T3 (da) | 2015-05-18 | 2019-08-05 | Tolero Pharmaceuticals Inc | Alvocidib-prodrugs, der har øget biotilgængelighed |
| PE20180672A1 (es) | 2015-05-29 | 2018-04-19 | Agenus Inc | Anticuerpos anti-ctla-4 y metodos de uso de los mismos |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| PE20181151A1 (es) | 2015-07-30 | 2018-07-17 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| RU2729371C1 (ru) | 2015-10-02 | 2020-08-06 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела, специфические к pd1 и tim3 |
| CA3006462C (en) | 2015-12-14 | 2023-10-31 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| CN109069570A (zh) * | 2015-12-16 | 2018-12-21 | 默沙东公司 | 抗lag3抗体和抗原结合片段 |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| JP7261379B2 (ja) | 2016-06-20 | 2023-04-20 | カイマブ・リミテッド | 抗ｐｄ－ｌ１抗体 |
| TW202436356A (zh) | 2016-10-11 | 2024-09-16 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| US11464869B2 (en) * | 2016-11-14 | 2022-10-11 | Takeda Pharmaceutical Company Limited | Non-adult human dosing of brentuximab vedotin |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| WO2018127710A1 (en) | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| EP3606946B1 (en) | 2017-04-03 | 2022-08-24 | F. Hoffmann-La Roche AG | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| EP4516809A2 (en) | 2017-04-05 | 2025-03-05 | F. Hoffmann-La Roche AG | Bispecific antibodies specifically binding to pd1 and lag3 |
| CR20190434A (es) | 2017-04-05 | 2019-11-01 | Hoffmann La Roche | Anticuerpos anti-lag3 |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| US11339218B2 (en) | 2017-05-10 | 2022-05-24 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Human monoclonal antibodies against LAG3 and uses thereof |
| CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| KR102713203B1 (ko) * | 2017-05-30 | 2024-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| AU2018287519B2 (en) | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| KR20200021087A (ko) | 2017-06-22 | 2020-02-27 | 노파르티스 아게 | Cd73에 대한 항체 분자 및 이의 용도 |
| JP2020525483A (ja) | 2017-06-27 | 2020-08-27 | ノバルティス アーゲー | 抗ｔｉｍ−３抗体のための投与レジメンおよびその使用 |
| WO2019011306A1 (en) * | 2017-07-13 | 2019-01-17 | Nanjing Leads Biolabs Co., Ltd. | LAG-3 BINDING ANTIBODIES AND USES THEREOF |
| KR20200031659A (ko) | 2017-07-20 | 2020-03-24 | 노파르티스 아게 | 항-lag-3 항체의 투여 요법 및 그의 용도 |
| US11390679B2 (en) | 2017-08-30 | 2022-07-19 | Phanes Therapeutics, Inc. | Anti-LAG-3 antibodies and uses thereof |
| US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| WO2019092452A1 (en) | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| TW201922291A (zh) | 2017-11-16 | 2019-06-16 | 瑞士商諾華公司 | 組合療法 |
| TW201925782A (zh) | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
| WO2019129137A1 (zh) * | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| EP3746480A1 (en) | 2018-01-31 | 2020-12-09 | F. Hoffmann-La Roche AG | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
| EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| US11661452B2 (en) * | 2018-03-20 | 2023-05-30 | WuXi Biologics Ireland Limited | Anti-lag-3 antibody polypeptide |
| WO2019180201A2 (en) * | 2018-03-22 | 2019-09-26 | Keires Ag | Antagonistic antigen binding proteins |
| US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
| EP3778639A4 (en) | 2018-04-02 | 2021-06-09 | Mab-Venture Biopharm Co., Ltd. | LYMPHOCYTE ANTIGEN-3 (LAG-3) BINDING ANTIBODY AND ITS USES |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN112261970B (zh) | 2018-07-10 | 2025-02-07 | 诺华股份有限公司 | 3-(5-羟基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其在治疗ikaros家族锌指2(ikzf2)依赖性疾病中的用途 |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| US20230053449A1 (en) | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
| MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
| CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| CN113227138A (zh) | 2018-12-21 | 2021-08-06 | 诺华股份有限公司 | IL-1β结合抗体的用途 |
| WO2020127965A1 (en) | 2018-12-21 | 2020-06-25 | Onxeo | New conjugated nucleic acid molecules and their uses |
| EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| BR112021011351A2 (pt) | 2018-12-21 | 2021-11-16 | Novartis Ag | Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica |
| WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2021009764A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| JP7547360B2 (ja) | 2019-03-22 | 2024-09-09 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法 |
| CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| AU2020370832A1 (en) | 2019-10-21 | 2022-05-19 | Novartis Ag | TIM-3 inhibitors and uses thereof |
| TW202128166A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | 組合療法 |
| WO2021123902A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| EP4087922A4 (en) | 2020-01-07 | 2024-01-10 | Board of Regents, The University of Texas System | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| WO2021144657A1 (en) | 2020-01-17 | 2021-07-22 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| IL298262A (en) | 2020-06-23 | 2023-01-01 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4178611A1 (en) | 2020-07-07 | 2023-05-17 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| JP2023548529A (ja) | 2020-11-06 | 2023-11-17 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| CN116514971B (zh) | 2020-12-10 | 2023-10-27 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
| AU2022355381A1 (en) | 2021-09-29 | 2024-05-02 | Akeso Biopharma, Inc. | Anti-lag3 antibody, pharmaceutical composition and use |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| CN118302446A (zh) * | 2021-11-01 | 2024-07-05 | 科望(苏州)生物医药科技有限公司 | 新型抗lag3抗体 |
| MX2024007300A (es) | 2021-12-16 | 2024-06-28 | Valerio Therapeutics | Nuevas moleculas de acido nucleico conjugado y sus usos. |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| RS58705B1 (sr) * | 2013-09-20 | 2019-06-28 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
-
2015
- 2015-01-26 EP EP21201919.4A patent/EP3988572A1/en active Pending
- 2015-01-26 EP EP15705137.6A patent/EP3099716A1/en not_active Withdrawn
- 2015-01-26 SI SI201531761T patent/SI3556775T1/sl unknown
- 2015-01-26 HU HUE19161885A patent/HUE057817T2/hu unknown
- 2015-01-26 ES ES19161885T patent/ES2902369T3/es active Active
- 2015-01-26 CN CN201580006297.5A patent/CN105992595A/zh active Pending
- 2015-01-26 PL PL19161885T patent/PL3556775T3/pl unknown
- 2015-01-26 BR BR112016017174A patent/BR112016017174A2/pt active Search and Examination
- 2015-01-26 HR HRP20212033TT patent/HRP20212033T1/hr unknown
- 2015-01-26 RS RS20211606A patent/RS62788B1/sr unknown
- 2015-01-26 EP EP19161885.9A patent/EP3556775B1/en active Active
- 2015-01-26 KR KR1020227036733A patent/KR20220147714A/ko not_active Ceased
- 2015-01-26 US US15/108,729 patent/US20160326248A1/en not_active Abandoned
- 2015-01-26 SM SM20220002T patent/SMT202200002T1/it unknown
- 2015-01-26 MX MX2016009010A patent/MX2016009010A/es unknown
- 2015-01-26 CA CA2937503A patent/CA2937503A1/en active Pending
- 2015-01-26 JP JP2016548710A patent/JP2017505773A/ja active Pending
- 2015-01-26 WO PCT/US2015/012916 patent/WO2015116539A1/en active Application Filing
- 2015-01-26 KR KR1020167023120A patent/KR20160106762A/ko not_active Ceased
- 2015-01-26 LT LTEP19161885.9T patent/LT3556775T/lt unknown
- 2015-01-26 DK DK19161885.9T patent/DK3556775T3/da active
- 2015-01-26 PT PT191618859T patent/PT3556775T/pt unknown
- 2015-01-26 EA EA201691361A patent/EA201691361A1/ru unknown
-
2016
- 2016-07-08 MX MX2022007800A patent/MX2022007800A/es unknown
-
2018
- 2018-02-09 US US15/893,102 patent/US20180244773A1/en not_active Abandoned
-
2019
- 2019-08-22 JP JP2019151663A patent/JP2020015737A/ja active Pending
-
2020
- 2020-09-09 US US17/016,092 patent/US20210122820A1/en not_active Abandoned
-
2022
- 2022-01-18 CY CY20221100044T patent/CY1124977T1/el unknown
- 2022-02-25 JP JP2022027920A patent/JP2022068355A/ja active Pending
-
2023
- 2023-07-28 US US18/227,636 patent/US20240150459A1/en active Pending
-
2024
- 2024-11-01 JP JP2024192583A patent/JP2025020283A/ja active Pending
-
2025
- 2025-01-17 US US19/030,949 patent/US20250197495A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240150459A1 (en) | 2024-05-09 |
| ES2902369T3 (es) | 2022-03-28 |
| SMT202200002T1 (it) | 2022-03-21 |
| US20210122820A1 (en) | 2021-04-29 |
| US20250197495A1 (en) | 2025-06-19 |
| JP2017505773A (ja) | 2017-02-23 |
| US20180244773A1 (en) | 2018-08-30 |
| HUE057817T2 (hu) | 2022-06-28 |
| US20160326248A1 (en) | 2016-11-10 |
| MX2022007800A (es) | 2022-07-19 |
| BR112016017174A2 (pt) | 2017-10-03 |
| JP2022068355A (ja) | 2022-05-09 |
| EP3988572A1 (en) | 2022-04-27 |
| CA2937503A1 (en) | 2015-08-06 |
| JP2020015737A (ja) | 2020-01-30 |
| PT3556775T (pt) | 2021-12-31 |
| PL3556775T3 (pl) | 2022-01-31 |
| JP2025020283A (ja) | 2025-02-12 |
| MX2016009010A (es) | 2017-01-18 |
| CY1124977T1 (el) | 2022-11-25 |
| KR20220147714A (ko) | 2022-11-03 |
| EP3556775A1 (en) | 2019-10-23 |
| SI3556775T1 (sl) | 2022-02-28 |
| WO2015116539A1 (en) | 2015-08-06 |
| HRP20212033T1 (hr) | 2022-04-01 |
| LT3556775T (lt) | 2022-01-25 |
| EP3556775B1 (en) | 2021-11-17 |
| KR20160106762A (ko) | 2016-09-12 |
| EP3099716A1 (en) | 2016-12-07 |
| RS62788B1 (sr) | 2022-02-28 |
| EA201691361A1 (ru) | 2016-12-30 |
| CN105992595A (zh) | 2016-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| SI3354729T1 (sl) | Protitelesa anti-garp | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3193929T3 (da) | Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer | |
| EP3182987C0 (en) | Humanized anti-tau antibodies | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| IL247299B (en) | Complement component c5 antibodies | |
| DK3183272T3 (da) | Asymmetriske multispecifikke antistoffer | |
| DK3126395T3 (da) | Multispecifikke antistoffer | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| CL2016001742A1 (es) | Anticuerpos anti-baff novedosos | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| PT3215530T (pt) | Anticorpos de il-6 melhorados | |
| LT3092003T (lt) | Naujas anti-netrino-1 antikūnas | |
| DK3218396T3 (da) | Fremgangsmåde til fremstilling af højaffinitets antistoffer |